Project Grant R01CA303110
Award Date 8/15/26
Completion Date 7/31/31
Dollars Obligated $577K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35205, USA
Similar Awards
- Federal Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026 through March 31, 2028. The award supports research investigating dual-targeting therapeutic approaches for acute myeloid leukemia (AML) by combining CD123-directed natural killer (NK) cell engager therapy with BCL-2 inhibition. The project focuses on evaluating the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan a $646,881 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2031. This award supports research targeting ASH1L (Absent, Small or Homeotic 1-Like), a histone methyltransferase implicated in acute leukemia development. The project focuses on the discovery and development of first-in-class small molecule inhibitors that...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $885,632 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded April 2, 2026, with completion targeted for March 31, 2028. The grant funds research to interrogate the relationship between erythroid differentiation and BCL-XL dependency in TP53-mutated acute myeloid leukemia (AML). The research addresses a critical clinical gap: TP53-mutated AML,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $422,649 Project Grant to the University of Illinois at Chicago, effective June 1, 2026, through May 31, 2028, under the Cancer Biology Research program (CFDA 93.396). This research initiative addresses health disparities in acute myeloid leukemia (AML) treatment outcomes, specifically investigating why Black AML patients with nucleophosmin mutations (NPM1MUT) and wild-type FMS-like receptor tyrosine kinase (FLT3-WT)...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Maryland, Baltimore a $399,829 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on May 13, 2026, to support research on protein degradation strategies to overcome menin inhibitor drug resistance in acute leukemias. The project, which extends through April 30, 2028, focuses on developing proteolysis-targeting chimeras (PROTACs) as a therapeutic approach to address rapid resistance...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $434,969 to the University of Pennsylvania on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate cellular mechanisms underlying acute myeloid leukemia (AML) persistence during FLT3 (Fms-like tyrosine kinase 3) inhibitor therapy. The five-year project, completing April 30, 2031, combines genetically engineered mouse models with human specimen analysis to determine which leukemic cell...
- Federal Grant Award Summary The University of Virginia received a $192,887 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) on May 8, 2026, with an ultimate completion date of April 30, 2029. This award supports biomedical research training and workforce development focused on acute myeloid leukemia (AML) risk stratification and therapeutic discovery. The project delivers research services centered on sphingolipid-guided patient...
- Federal Grant Award Summary Baylor College of Medicine received a $160,500 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective July 10, 2025, with completion targeted for June 30, 2027. The award funds the development and investigation of in vivo murine models to examine the role of caspase-2 in nucleophosmin-mutated acute myeloid leukemia (NPM1C+ AML). The research deliverables include the establishment of transgenic mouse...
- Federal Grant Award Summary Baylor College of Medicine received a $2.4 million Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective August 15, 2025 through July 31, 2029. The award funds research investigating the role of RNA sequestration in acute myeloid leukemia (AML), specifically examining how the RNA helicase DDX6 (DEAD-Box Helicase 6) regulates post-transcriptional processes critical to leukemia development and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Beckman Research Institute of the City of Hope a $517,090 Project Grant under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, to investigate the role and biological function of a novel signature gene designated AL021978.1 (A978) in Philadelphia chromosome (PH)-positive and PH-like B-cell acute lymphoblastic leukemia (B-ALL). The research aims to address high-risk leukemia subtypes with survival...